275 related articles for article (PubMed ID: 9824107)
1. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C.
Dutta U; Kench J; Byth K; Khan MH; Lin R; Liddle C; Farrell GC
Hum Pathol; 1998 Nov; 29(11):1279-84. PubMed ID: 9824107
[TBL] [Abstract][Full Text] [Related]
2. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
3. Low MIB-1 labeling index in anti-HCV positive hepatocellular carcinoma.
Watanuki A; Ohwada S; Fukusato T; Kawate S; Makita F; Morishita Y
Int J Oncol; 1998 Nov; 13(5):1017-22. PubMed ID: 9772294
[TBL] [Abstract][Full Text] [Related]
4. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience.
Roayaie S; Haim MB; Emre S; Fishbein TM; Sheiner PA; Miller CM; Schwartz ME
Ann Surg Oncol; 2000 Dec; 7(10):764-70. PubMed ID: 11129425
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.
Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA
World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214
[TBL] [Abstract][Full Text] [Related]
6. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.
Xiao EH; Li JQ; Huang JF
World J Gastroenterol; 2004 Jan; 10(2):190-4. PubMed ID: 14716820
[TBL] [Abstract][Full Text] [Related]
7. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma.
Wu PC; Lau VK; Fang JW; Lai VC; Lai CL; Lau JY
Liver; 1999 Oct; 19(5):444-51. PubMed ID: 10533805
[TBL] [Abstract][Full Text] [Related]
8. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
9. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
10. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
[TBL] [Abstract][Full Text] [Related]
11. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.
Lok AS; Everhart JE; Di Bisceglie AM; Kim HY; Hussain M; Morgan TR;
Hepatology; 2011 Aug; 54(2):434-42. PubMed ID: 21374690
[TBL] [Abstract][Full Text] [Related]
12. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
13. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 positivity in B and C hepatitis and hepatocellular carcinomas.
Yildiz L; Baris S; Aydin O; Kefeli M; Kandemir B
Hepatogastroenterology; 2008; 55(88):2207-10. PubMed ID: 19260506
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphism of BCL-2 (rs2279115) with susceptibility to HCV-related hepatocellular carcinoma.
Ahmed HS; Wahab EA; Elhady HA; Elgerby MM
Immunol Res; 2020 Aug; 68(4):189-197. PubMed ID: 32623689
[TBL] [Abstract][Full Text] [Related]
17. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 protein expression in acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Nakopoulou L; Stefanaki K; Vourlakou C; Manolaki N; Gakiopoulou H; Michalopoulos G
Pathol Res Pract; 1999; 195(1):19-24. PubMed ID: 10048090
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for development of hepatocellular carcinoma among Australians with hepatitis C: a case-control study.
Dutta U; Byth K; Kench J; Khan MH; Coverdale SA; Weltman M; Lin R; Liddle C; Farrell GC
Aust N Z J Med; 1999 Jun; 29(3):300-7. PubMed ID: 10868491
[TBL] [Abstract][Full Text] [Related]
20. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
